As a core downstream effector, mTOR regulates tumor growth and survival through the mTORC1/2 complex [25] and is a key therapeutic target for RCC, with mTOR inhibitors (such as everolimus) already in clinical use. The gene discussed is MTOR; the disease is neoplasm.